RxDoctor Payments Data

Andrew Clementz, MD

Family Medicine · Atlanta, GANPI 1689171621

Payments from drug & device makers

$1,480in general payments, 2019–2025

Across 48 payments — averaging $30.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$321
  • Pfizer$304
  • AstraZeneca$144
  • Exact Sciences$105
  • Amgen$102
  • Sumitomo Pharma America, Inc.$100
  • plus $404 from 12 others

What the payments were for

  • Food & beverage$1,480100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,480 in reported general payments places this provider in the 65th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$128,630
Medicare patients
291
Services billed
1,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$39,724
OzempicSemaglutide25$25,222
JanuviaSitagliptin Phosphate15$21,536
WegovySemaglutide13$16,960
MounjaroTirzepatide14$14,463
SymbicortBudesonide/Formoterol Fumarate12$3,673
Atorvastatin Calcium140$1,591
Rosuvastatin Calcium93$1,520
Levothyroxine Sodium66$1,519
SynthroidLevothyroxine Sodium12$1,195
Amlodipine Besylate128$1,127
Pantoprazole Sodium66$1,064
Losartan Potassium73$1,004
Valsartan20$988
Esomeprazole Magnesium12$973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$55$42,18238 claims
PfizerEliquis$304$39,72445 claims
Lilly USA, LLCMounjaro$321$14,46314 claims
AstraZenecaSymbicort$144$3,67312 claims
AbbVieSynthroid$93$1,19512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →